Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: Is risk stratification useful?

Abstract

---

Highlights

•

MASCC risk index score appears predictive of which NF patients will be low risk.

•

MASCC predicts high-risk NF patients in half of cases.

•

Low-risk patients per MASCC scoring endure fewer complications and lower mortality.

---

Objective

This study aimed to evaluate the utility of risk stratification of gynecologic oncology patients with neutropenic fever (NF).

Methods

A retrospective chart review of gynecologic cancer patients admitted with NF from 2007 to 2011 was performed, wherein demographic, oncologic, and NF characteristics (hospitalization length, complications, and death) were collected. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score was calculated; low risk was considered ≥ 21. SAS 9.2 was used for statistical analyses.

Results

Eighty-three patients met the study criteria. Most (92%) were Caucasian and had advanced stage disease (71%). Primary tumors were 58% ovary, 35% endometrium, and 6% cervix. All patients were receiving chemotherapy on admission (72% for primary, 28% for recurrent disease). Forty-eight percent had a positive culture, and most (58%) positive cultures were urine. Seventy-six percent of patients were considered low risk. High-risk patients were more likely to have a severe complication (10% versus 50%, p = 0.0003), multiple severe complications (3% versus 20%, p = 0.0278), ICU admission (2% versus 40%, p < 0.0001), overall mortality (2% versus 15%, p = 0.0417), and death due to neutropenic fever (0% versus 15%, p = 0.0124). MASCC had a positive predictive value of 50% and negative predictive value of 90%. The median MASCC score for all patients was 22 (range, 11–26), but the median MASCC score for those with death or a severe complication was 17 (range, 11–24).

Conclusion

Based on this pilot data, MASCC score appears promising in determining suitability for outpatient management of NF in gynecologic oncology patients. Prospective study is ongoing to confirm safety and determine impact on cost.

Purchase $39.95